Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
Open Access
- 27 December 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 4 (12), e353
- https://doi.org/10.1371/journal.pmed.0040353
Abstract
Oncolytic viruses hold much promise for clinical treatment of many cancers, but a lack of systemic delivery and insufficient tumor cell killing have limited their usefulness. We have previously demonstrated that vaccinia virus strains are capable of systemic delivery to tumors in mouse models, but infection of normal tissues remains an issue. We hypothesized that interferon-beta (IFN-β) expression from an oncolytic vaccinia strain incapable of responding to this cytokine would have dual benefits as a cancer therapeutic: increased anticancer effects and enhanced virus inactivation in normal tissues. We report the construction and preclinical testing of this virus. In vitro screening of viral strains by cytotoxicity and replication assay was coupled to cellular characterization by phospho-flow cytometry in order to select a novel oncolytic vaccinia virus. This virus was then examined in vivo in mouse models by non-invasive imaging techniques. A vaccinia B18R deletion mutant was selected as the backbone for IFN-β expression, because the B18R gene product neutralizes secreted type-I IFNs. The oncolytic B18R deletion mutant demonstrated IFN-dependent cancer selectivity and efficacy in vitro, and tumor targeting and efficacy in mouse models in vivo. Both tumor cells and tumor-associated vascular endothelial cells were targeted. Complete tumor responses in preclinical models were accompanied by immune-mediated protection against tumor rechallenge. Cancer selectivity was also demonstrated in primary human tumor explant tissues and adjacent normal tissues. The IFN-β gene was then cloned into the thymidine kinase (TK) region of this virus to create JX-795 (TK−/B18R−/IFN-β+). JX-795 had superior tumor selectivity and systemic intravenous efficacy when compared with the TK−/B18R− control or wild-type vaccinia in preclinical models. By combining IFN-dependent cancer selectivity with IFN-β expression to optimize both anticancer effects and normal tissue antiviral effects, we were able to achieve, to our knowledge for the first time, tumor-specific replication, IFN-β gene expression, and efficacy following systemic delivery in preclinical models.Keywords
This publication has 37 references indexed in Scilit:
- Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic AdenovirusMolecular Therapy, 2007
- Strategies to achieve systemic delivery of therapeutic cells and microbes to tumorsExpert Opinion on Biological Therapy, 2006
- Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSFMolecular Therapy, 2006
- Characteristics of tumor-associated endothelial cells derived from glioblastoma multiformeNeurosurgical Focus, 2006
- Oncolytic Virotherapy: Approaches to Tumor Targeting and Enhancing Antitumor EffectsSeminars in Oncology, 2005
- Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genesCancer Gene Therapy, 2002
- RNA viruses as virotherapy agentsCancer Gene Therapy, 2002
- CD4+T Helper Cell-Independent Antitumor Response Mediated by Murine IFN-βGene Delivery in Immunocompetent MiceJournal of Interferon & Cytokine Research, 2002
- Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastasesJCI Insight, 2001
- Reovirus as a novel oncolytic agentJCI Insight, 2000